Skip to content

Risperidone

Perseris, Risperdal, Risperdal Consta (risperidone) is a small molecule pharmaceutical. Risperidone was first approved as Perseris on 1993-12-29. It is used to treat autistic disorder, bipolar disorder, dementia, schizophrenia, and schizophrenia spectrum and other psychotic disorders amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D. In addition, it is known to target D(3) dopamine receptor, alpha-1A adrenergic receptor, 5-hydroxytryptamine receptor 1E, alpha-1B adrenergic receptor, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2C, alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, histamine H1 receptor, 5-hydroxytryptamine receptor 1F, and e Lysozyme murein hydrolase. Risperdal's patents are valid until 2028-02-13 (FDA).
Trade Name Perseris, Risperdal, Risperdal Consta
Common Name Risperidone
Indication autistic disorder, bipolar disorder, dementia, schizophrenia, schizophrenia spectrum and other psychotic disorders, tourette syndrome
Drug Class Antipsychotics (risperidone type)
Risperidone
Get full access now